权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

SBIR Phase II: Bioelectrical Cell Enrichment, Sorting, and Recovery with On-Chip Sample Prep and Monitoring

SBIR 第二阶段：通过片上样品制备和监测进行生物电细胞富集、分选和回收

基本信息

批准号：
2222933
负责人：
Alexandra Hyler
金额：
$ 95.26万
依托单位：
CYTORECOVERY, INC.
依托单位国家：
美国
项目类别：
Cooperative Agreement
财政年份：
2023
资助国家：
美国
起止时间：
2023-02-15 至 2025-01-31
项目状态：
未结题

来源：
https://www.nsf.gov/awardsearch/showAward?AWD_ID=2222933&HistoricalAwards=false
关键词：
SBIR Phase II Bioelectrical Cell

项目摘要

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is a label-free, biological sample preparation and cell isolation platform for recovery of rare cells from a variety of sample inputs. Specifically, by carrying out sample preparation, manipulation, and monitoring on a single chip platform for selective cell recovery, the sample handling steps will be greatly reduced, thereby ensuring the maintenance of cell viability, improving sample consistency, and sustaining native cell behaviors. This recovered sample is essential for the development of cell-based therapies in regenerative medicine and cancer management. Personalized medicine also requires precision cell recoveries.This Small Business Technology Transfer (STTR) Phase I project will develop an electrically functional microfluidic sample manipulation platform for phenotype-selective recovery of cells, based on their biophysical attributes. Specifically, microfluidic designs will be integrated to swap cells from complex biological inputs into an optimized buffer to enable cell manipulation. Also, instrumentation will be developed for on-chip monitoring of the sample during various stages of the phenotype-selective cell recovery process. Further, a variety of sample inputs will be validated on the designed devices to ensure performance, consistency, and reliability for translation into commercial product lines.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小型企业创新研究(SBIR)第二阶段项目的更广泛的影响/商业潜力是一个无标签的生物样本制备和细胞分离平台，用于从各种样本输入中回收稀有细胞。具体地说，通过在单个芯片平台上进行样品制备、操作和监测以选择性地回收细胞，将大大减少样品处理步骤，从而确保维持细胞活力，提高样品一致性，并维持自然的细胞行为。这个回收的样本对于再生医学和癌症管理中基于细胞的疗法的发展至关重要。个性化医疗还需要精确的细胞回收。这个小企业技术转移(STTR)第一阶段项目将开发一个电子功能的微流控样品处理平台，用于基于细胞的生物物理属性进行表型选择性回收。具体地说，将整合微流控设计，将细胞从复杂的生物输入交换到优化的缓冲器中，以实现细胞操作。此外，还将开发用于在表型选择性细胞恢复过程的不同阶段对样本进行芯片监测的仪器。此外，各种样本输入将在设计的设备上进行验证，以确保转换为商业产品线的性能、一致性和可靠性。该奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。